Investment
Features
FeesSafety
Academy
More
Pluang+

Compare ADMA Biologics Inc (ADMA) vs Aspen Aerogels Inc (ASPN) Price & Performance

ADMA Biologics IncTrade
Aspen Aerogels IncTrade

Price performance (Past 24H)

Key statistics

ADMA Biologics Inc vs Aspen Aerogels Inc — how do they compare? ADMA Biologics Inc trades at $9.81 (market cap $2.22B), while Aspen Aerogels Inc trades at $6.15 (market cap $509.55M). The key difference: ADMA Biologics Inc is far larger — about 4.4× Aspen Aerogels Inc's market cap, and Aspen Aerogels Inc is trading nearer its 52-week high, ADMA Biologics Inc nearer its low. Which is the better fit depends on your goals.

ADMAASPN
Market Cap
$2.22B$509.55M
Sector
HealthTechnology
52-Week High
$20.38$8.82
52-Week Low
$7.60$2.57
Enterprise Value
$2.29B$482.96M

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

ADMA Biologics Inc

ADMA trades at $9.90, down 1.59% today, with strong profitability metrics including 64.71% gross margin and 41.9% ROE. Technical indicators show a bullish trend with support at $9-10, though RSI levels suggest overbought conditions. Recent earnings show mixed results with Q4 2025 beating expectations but Q1 and Q2 2026 missing estimates. The stock faces significant legal headwinds with multiple securities fraud lawsuits filed against the company.

Despite strong fundamentals and bullish analyst consensus (88.9% buy ratings), ADMA faces substantial legal risks from ongoing securities litigation that could impact shareholder value. The company's solid profit margins and growth trajectory provide upside potential, but investors should carefully weigh litigation risks against fundamental strength.

Aspen Aerogels Inc

ASPN's stock trades at $6.25, down 9.29% in the past 24 hours, with a bullish technical signal from moving averages but neutral oscillators. The company reported a net loss of $389.55M in 2025, with negative profit margins, though Q2 2026 revenue beat estimates and Q3 guidance projects sequential improvement. Recent news highlights growing Thermal Barrier sales and a Supplier of the Year award from General Motors.

The outlook remains speculative; analyst consensus is strongly bullish (82.61% buy ratings), but persistent losses and high cash burn pose significant risks. Upside depends on execution of revenue growth and cost management, while downside risks include competitive pressures and failure to achieve profitability.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About ADMA Biologics Inc

ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.

Read more on ADMA

About Aspen Aerogels Inc

Aspen Aerogels is an aerogel technology company that designs high-performance insulation. Its products are used in energy infrastructure and electric vehicles to provide thermal management and fire protection.

Read more on ASPN